Verve Therapeutics

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Boston, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

LOS ANGELES, CA / ACCESSWIRE / November 15, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Verve Therapeutics, Inc. ("Verve" or "the Company") (NASDAQ:VERV) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Verve Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

monday.com

Markets opened only slightly lower on Monday morning. Monday.com reported strong financial results and boosted its guidance for the rest of the year.

These 2 Stocks Are Making Big Monday Moves

Verve stock crashed Monday as safety concerns plagued its gene-editing approach to high cholesterol. VERV stock plummeted.

Verve Loses A Third Of Its Value As Safety Concerns Plague Its Gene-Editing Drug

Verve Therapeutics Inc. shares VERV, -2.12% fell 40% premarket on Monday after the biotech company on Sunday released early-stage clinical trial data on its experimental gene-editing treatment for high cholesterol.

Verve Therapeutics' stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment

Verve Therapeutics (NASDAQ: VERV ) stock is taking a beating on Monday after the genetic medicines company announced new clinical data. This clinical data comes from the company's phase 1b clinical trial of VERVE-101 as a treatment for patients with Heterozygous Familial Hypercholesterolemia.

Why Is Verve Therapeutics (VERV) Stock Down 39% Today?

LDL-C Reductions Up to 55% and Blood PCSK9 Protein Reductions Up to 84% Observed After a Single Infusion of VERVE-101 at Potentially Therapeutic Doses

Verve Therapeutics Announces Interim Data for VERVE-101 Demonstrating First Human Proof-of-Concept for In Vivo Base Editing with Dose-Dependent Reductions in LDL-C and Blood PCSK9 Protein in Patients with Heterozygous Familial Hypercholesterolemia

The consensus price target hints at a 160.7% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Predict a 160.72% Upside in Verve Therapeutics (VERV): Here's What You Should Know

Cathie Wood's ARK Invest family of ETFs focuses on the interrelated concepts of innovation and disruption. Verve Therapeutics, a holding in two of her better-known ETFs, appears primed for a sustained move higher.

1 Cathie Wood Stock to Buy Hand Over Fist Right Now

Transmedics Group Inc

TransMedics Group's transplant organ retrieval and delivery business is accelerating now that it doesn't have to rely on third parties for charter flights. Verve Therapeutics and its partnership with Eli Lilly could soon take a big step forward.

2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher

U.S. Food and Drug Administration (FDA) Clears Investigational New Drug Application for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia (HeFH)

Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results

Verve Therapeutics (VERV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Verve Therapeutics (VERV) Surges 28.0%: Is This an Indication of Further Gains?

Beam Therapeutics

Intuitive Surgical

Cathie Wood, the brilliant mind behind ARK Invest, is known for her unique ability to spot disruptive trends in stocks. Her investment strategies have made waves in the financial world, and millions of investors eagerly follow her every move.

Inside Cathie Wood's Portfolio: 3 Stocks She Is Betting Millions On

Eli Lilly

The trio was involved in a deal for gene-editing programs. The arrangement is potentially worth $600 million.

Why Beam and Verve Therapeutics Shares Soared While Eli Lilly Soured Today

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

Verve Stock Soars On $250 Million Eli Lilly Deal

Lilly Purchases Product Rights to Verve's Lead Cardiovascular Programs from Beam Therapeutics Lilly Purchases Product Rights to Verve's Lead Cardiovascular Programs from Beam Therapeutics

Verve and Lilly Relationship Expands to Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3

The FDA just gave it the go-ahead to test its lead gene-editing program in humans. But the young biotech will still likely need to raise money in a couple of years.

With 1 Roadblock Down, Is Verve Therapeutics a Buy Now?

BOSTON, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the lifting of the clinical hold and clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to conduct a clinical trial in the United States evaluating VERVE-101 for the treatment of heterozygous familial hypercholesterolemia (HeFH). VERVE-101 is an investigational, in vivo base editing medicine designed to be a single-course treatment that inactivates the PCSK9 gene in the liver to durably lower blood low-density lipoprotein cholesterol (LDL-C). HeFH is a prevalent and life-threatening inherited disease characterized by lifelong elevations in blood LDL-C and accelerated atherosclerotic cardiovascular disease (ASCVD).

Verve Therapeutics Announces Clearance of Investigational New Drug Application by the U.S. FDA for VERVE-101 in Patients with Heterozygous Familial Hypercholesterolemia

Amylyx Pharmaceuticals

Growth stocks have wilted under an avalanche of macro headwinds in late 2023. This broad sell-off, though, may have created some incredible bargains.

2 Incredible Growth Stocks Near 52-Week Lows to Buy Now

Verve Therapeutics (VERV) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Verve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?

Company to hold investor event in conjunction with data presentation on November 12, 2023 Company to hold investor event in conjunction with data presentation on November 12, 2023

Verve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association's Scientific Sessions 2023

BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:55 a.m. ET in New York.

Verve Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

BOSTON, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Frederick “Fred” T. Fiedorek, M.D., as chief medical officer (CMO). Andrew Bellinger, M.D., Ph.D., the current chief scientific officer (CSO) and CMO, will transition to the role of CSO.

Verve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D.

Cathie Wood has been steadily buying Verve Therapeutics shares this summer. An upcoming data readout could be a game changer for the company and its shareholders.

1 Cathie Wood Stock That Could Go Parabolic Soon

Verve Therapeutics (VERV) came out with a quarterly loss of $0.87 per share versus the Zacks Consensus Estimate of a loss of $0.91. This compares to loss of $0.84 per share a year ago.

Verve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue Estimates

heart-1 Initial Clinical Data Expected in the Fourth Quarter of 2023 Preclinical Studies and Clinical Operations Activities Underway to Support Initiation of Clinical Trials for VERVE-102 and VERVE-201 in 2024 Lp(a) Program Advancing in Collaboration with Lilly; Received $60 Million in Combined Upfront Payment and Equity Investment in August 2023 Well-capitalized with Cash Runway into 2026 BOSTON, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Verve Therapeutics, Inc., a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today reported recent company progress and financial results for the second quarter of 2023. “We are dedicated to bringing life-changing, once-and-done medicines to patients with cardiovascular disease,” said Sekar Kathiresan, M.D.

News for Verve Therapeutics Stock (VERV)